Precision Biosciences Inc.
Precision Biosciences Inc. is listed today as Precision BioSciences, Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2018 | $88 M | No. 2 | $50 to $250 million | equity | SEC | |
| Apr 2015 | $26 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Precision BioSciences, Inc., its revenue in fiscal 2025 came from these business segments: Operating $34.26 million (100%).
Annual report (SEC XBRL) · Dec 2025
Precision Biosciences Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2018).
SEC Form D · Jun 2018
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jun 2018
Products and services#
No products or services of Precision Biosciences Inc. are on record.
Investors#
5 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Fmr LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| venBio Global Strategic Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner, director (Form 3, 2019) | SEC Form 3 |
| venBio Global Strategic GP, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| venBio Global Strategic GP, Ltd. | Company | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Yao Tony Dung Ling | Person | not stated | not stated | Held Series B preferred stock, director (Form 3, 2019) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 40 investors.
Largest shareholders today
Institutions holding Precision BioSciences, Inc. shares, as of Sep 30, 2026.
- Lynx1 Capital Management LP$17 M9.87%
- Aberdeen Group plc$14 M7.98%
- Bleichroeder LP$13 M7.22%
- BlackRock, Inc.$10 M5.75%
- Boothbay Fund Management, LLC$8 M4.82%
- Vanguard Capital Management LLC$7 M3.95%
- Driehaus Capital Management LLC$6 M3.39%
- Parkman Healthcare Partners LLC$5 M3.00%
- Affinity Asset Advisors, LLC$4 M2.31%
- Geode Capital Management, LLC$4 M2.27%
- ArrowMark Colorado Holdings LLC$3 M1.63%
- State Street Corp$3 M1.56%
- Octagon Capital Advisors LP$3 M1.54%
- Schonfeld Strategic Advisors LLC$2 M0.98%
- Two Sigma Investments, LP$2 M0.88%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Abid Ansari | Executive officer | Jun 2018 |
| Derek Jantz | Executive officer | Jun 2018 |
| Jeff Smith | Executive officer | Jun 2018 |
| Matthew Kane | Executive officer | Jun 2018 |
| Todd Melby | Executive officer | May 2015 |
| Derek Jantz | Director | Jun 2018 |
| Matthew Kane | Director | Jun 2018 |
| Robert Adelman | Director | Jun 2018 |
| Tony Yao | Director | Jun 2018 |
| Ben Auspitz | Director | May 2015 |
Went public since 2019. Its SEC number is that of a company listed on a stock exchange.